---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000029"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:22:03.992461+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akebia reports Q4 2023 net income $0.6M, Auryxia $53.2M; vadadustat PDUFA Mar 27

## Summary
- Net income of $0.6M in Q4 2023 vs net loss $6.1M a year ago; full-year net income $51.9M vs loss $94.2M in 2022.
- Auryxia net product revenue $53.2M in Q4, $170.3M full year, within guidance of $170-175M.
- Vadadustat PDUFA date March 27, 2024; Akebia preparing for potential U.S. launch.
- Closed $55M BlackRock term loan and raised $26M via ATM; cash $42.9M at year-end, sufficient for 24 months if vadadustat approved.
- Appointed Nicholas Grund as Chief Commercial Officer; introduced early-stage pipeline programs AKB-9090 and AKB-10108.

## SEC filing metadata
- accession: 0001517022-24-000029
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/0001517022-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/akba-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000029
- JSON: https://secwatch.observer/filing/0001517022-24-000029.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000029.txt

## Key facts
- Earnings Releases
  Akebia Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $56.2 million, net income $0.6 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $56.2 million
  - Net income: $0.6 million
  - Result: reported results
  source text: Financial Results • Revenues: Total revenues were $56.2 million for the fourth quarter of 2023 compared to $55.8 million for the fourth quarter of 2022, and $194.6 million for the full-year 2023 compared to $292.5 million for the full-year 2022. ◦ Net product revenues were $53.2 million for the fourth quarter of 2023 compared to $50.3 million for the fourth quarter of 2022, and $170.3 million for the full-year 2023 compared to $176.9 million for the full-year 2022. ◦ License, collaboration and other revenues were $3.0 million for the fourth quarter of 2023 compared to $5.5 million for the fourth quarter of 2022, and $24.3 million for the full-year 2023 compared to $115.5 million for the full-year 2022. • COGS: Cost of goods sold was $18.7 million for the fourth quarter of 2023 compared to a benefit of $3.4 million for the fourth quarter of 2022, and $74.1 million for the full-year 2023 compared to $85.6 million for the full-year 2022. Akebia continues to record a non-cash intangible am
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/0001517022-24-000029-index.htm
- Earnings Releases
  Akebia Therapeutics, Inc. reported the fiscal year ended December 31, 2023 results: revenue $194.6 million, net income $51.9 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $194.6 million
  - Net income: $51.9 million
  - Result: reported results
  source text: Financial Results • Revenues: Total revenues were $56.2 million for the fourth quarter of 2023 compared to $55.8 million for the fourth quarter of 2022, and $194.6 million for the full-year 2023 compared to $292.5 million for the full-year 2022. ◦ Net product revenues were $53.2 million for the fourth quarter of 2023 compared to $50.3 million for the fourth quarter of 2022, and $170.3 million for the full-year 2023 compared to $176.9 million for the full-year 2022. ◦ License, collaboration and other revenues were $3.0 million for the fourth quarter of 2023 compared to $5.5 million for the fourth quarter of 2022, and $24.3 million for the full-year 2023 compared to $115.5 million for the full-year 2022. • COGS: Cost of goods sold was $18.7 million for the fourth quarter of 2023 compared to a benefit of $3.4 million for the fourth quarter of 2022, and $74.1 million for the full-year 2023 compared to $85.6 million for the full-year 2022. Akebia continues to record a non-cash intangible am
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/0001517022-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.